Therapeutic drug monitoring is indicated when the gap between desired effect and harmful effect is small and when blood concentration better predicts outcome than dose. Narrow therapeutic index drugs such as antiepileptics, aminoglycosides, lithium, digoxin, and certain immunosuppressants commonly meet these criteria. Clinical guidelines and pharmacology texts emphasize measurement when concentration guides safe and effective dosing rather than fixed dosing alone.
Clinical indications
Indications include prolonged or unpredictable pharmacokinetics, end-organ dysfunction, potential for major drug interactions, pregnancy, extremes of age, and suspected nonadherence. Nikolaos N. Patsalos University College London has described the central role of monitoring for many antiepileptic drugs because serum level correlates better with seizure control and toxicity than administered dose. Malcolm Rowland University of Manchester and Thomas N. Tozer University of Florida explain that when a compound shows high interindividual variability in absorption, distribution, metabolism, or excretion, monitoring is a practical tool to individualize therapy. Pharmacokinetic variability is therefore a primary trigger for TDM.
Causes and consequences
Causes of the need for TDM include genetic polymorphisms in metabolizing enzymes, drug interactions that inhibit or induce clearance, acute illness, and reduced renal or hepatic function. Consequences of failing to monitor can be either subtherapeutic exposure with treatment failure or harmful accumulation leading to toxicity. In immunosuppression, for example, underexposure increases graft rejection risk while overexposure raises infection and malignancy risks. These outcomes have direct human and territorial impacts when laboratory resources are limited and clinicians must balance risks without timely levels.
Practical application requires defining target concentrations, timing sampling appropriately, and integrating clinical context. For drugs with time-dependent toxicity, trough levels are often most informative. For concentration-dependent efficacy or toxicity, peak measurements may be required. Adherence assessment via unexpected concentrations also informs management.
Environmental and cultural nuances matter: laboratory access, cost, and trust in blood testing influence whether TDM is feasible in low-resource and indigenous communities, affecting equity of care. Where assays are unavailable, clinicians rely more on clinical monitoring and conservative dosing. Overall, therapeutic drug monitoring is indicated when measurement meaningfully reduces uncertainty about benefit versus harm and when actionable concentration targets exist. When such conditions hold, TDM moves care from population averages toward safer, individualized dosing.